SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces the publication of a peer-reviewed journal
article featuring analytical validation results demonstrating the
high sensitivity of the Company's Target Selector™ testing for
EGFR, BRAF, and KRAS mutations in plasma
circulating tumor DNA (ctDNA). The article was published in the
journal, PLOS ONE, Volume 14, October
2019, and will also be included as part of a
special collection of topical articles, entitled Targeted
Anticancer Therapies And Precision Medicine In
Cancer.
Key points from the article include:
- Target Selector™ testing for EGFR, BRAF, and
KRAS mutations has been validated to an ultra-sensitive
single copy level, with a limit of detection (LOD) of 0.02% or
better
- Biocept's biomarker tests provide coverage for the most common
actionable mutations associated with clinical guidelines for
targeted cancer therapy
- Target Selector™ tests performed in Biocept's laboratory
provide a commercial turnaround time of 3-4 days, and offer a
cost-effective strategy to guide treatment decisions and monitor
therapeutic response
"Biocept's patented Switch-Blocker™ technology uniquely
amplifies mutations of interest from the blood of patients with
cancer, while blocking wild type DNA. This enables very high
sensitivity and detection down to a single gene copy," said
Jason Poole, Vice President of
Research and Development at Biocept and the study's lead author.
"We are very pleased to have this analytical validation published
in PLOS ONE, and believe the results demonstrate the high
sensitivity and performance of our novel liquid biopsy assays,
which are designed to provide oncologists with the information they
need to select the right targeted therapy for their patients."
Michael Nall, Biocept's President
and CEO added, "This peer-reviewed publication provides further
data supporting the clinical utility of our Target Selector™
technologies focused on actionable biomarkers. This testing is
available as a laboratory service in our CLIA-certified and
CAP-accredited facility and in Research Use Only (RUO) kits that
can be performed in a customer's laboratory. Target Selector™
liquid biopsy continues to emerge as an important tool to
cost-effectively qualify patients for therapy and, importantly,
monitor therapeutic response and disease progression for physicians
and their patients with cancer. Biocept provides physicians and
hospital systems with the choice of liquid biopsy laboratory
services, kits and blood collection tubes, as customers assess ways
to adopt liquid biopsy in their standard of care protocols."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with information for
treating and monitoring patients diagnosed with cancer. The
Company's patented Target Selector™ liquid biopsy technology
platform captures and analyzes tumor-associated molecular markers
in both circulating tumor cells (CTCs) and in plasma (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including,
without limitation, statements as to our ability to improve the
outcomes of patients diagnosed with cancer and the potential
clinical utility of our proprietary technology platform, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at http://www.sec.gov/.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-ctdna-platform-demonstrates-single-copy-detection-for-egfr-braf-and-kras-mutations-study-results-published-in-peer-reviewed-journal-plos-one-300932753.html
SOURCE Biocept, Inc.